

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Group. The Directors collectively and individually accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquires, that to the best of their knowledge and belief there are no other facts the omission of which would make any statement in this announcement misleading.



Tong Ren Tang Technologies Co., Ltd.

北京同仁堂科技發展股份有限公司

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code on GEM: 8069)

(Stock Code on Main Board: 1666)

**TRANSFER OF LISTING FROM THE GROWTH ENTERPRISE
MARKET TO THE MAIN BOARD OF THE STOCK EXCHANGE OF
HONG KONG LIMITED**

Financial adviser to the Company



On 30 April 2010, an application was made by the Company to the Stock Exchange for the transfer of listing from GEM to the Main Board. The Company has applied for the listing of, and permission to deal in 87,320,000 H Shares in issue on the Main Board by way of transfer of listing from GEM to the Main Board. The approval-in-principle has been granted by the Stock Exchange on 18 June 2010 for the H Shares to be listed on the Main Board and delisted from GEM, according to Listing Rule 9A.09(6). The Company also obtained the approval from China Securities Regulatory Commission in connection with the implementation of the Transfer on 12 April 2010.

All pre-conditions for the Transfer as set out in the Listing Rules have been fulfilled in relation to the Company and its H Shares.

The last day of dealings in the H Shares on GEM will be 8 July 2010. Dealings in the H Shares on the Main Board (Stock code: 1666) will commence at 9:30 a.m. on 9 July 2010.

The Transfer will have no effect on the existing share certificates in respect of the H Shares which will continue to be good evidence of legal title and be valid for trading, settlement and registration purposes and will not involve any transfer or exchange of the existing share certificates. No change will be made to the existing share certificates, board lot size, trading currency and the share registrars of the H Shares in connection with the Transfer.

Reference is made to the announcement issued by the Company dated 30 April 2010 in relation to the formal application submitted to the Stock Exchange for the Transfer pursuant to Chapter 9A of the Main Board Listing Rules.

TRANSFER OF THE LISTING OF THE H SHARES FROM GEM TO THE MAIN BOARD

On 30 April 2010, an application was made by the Company to the Stock Exchange for the transfer of listing from GEM to the Main Board. The Company has applied for the listing of, and permission to deal in 87,320,000 H Shares in issue on the Main Board by way of transfer of listing from GEM to the Main Board. The approval-in-principle has been granted by the Stock Exchange on 18 June 2010 for the H Shares to be listed on the Main Board and delisted from GEM, according to Listing Rule 9A.09(6). The Company also obtained the approval from China Securities Regulatory Commission in connection with the implementation of the Transfer on 12 April 2010.

All pre-conditions for the Transfer as set out in the Listing Rules have been fulfilled in relation to the Company and its H Shares.

REASONS FOR THE TRANSFER

The Company principally engages in the manufacture and sale of Chinese patent medicine. The Company's products include Liuwei Dihuang Pills (六味地黃丸), Niu Huang Jiedu Tablets (牛黃解毒片), Ganmao Qingre Granule (感冒清熱顆粒), Jin Kui Shenqi Pills (金匱腎氣丸) and Shengmai Liquor (生脈飲). Since the listing of the H Shares on GEM on 31 October 2000, the business of the Company has grown steadily and the Company has improved its public profile.

The Directors believe that the listing of the H Shares on the Main Board will enhance the profile of the Company and could improve the trading liquidity of the H Shares. The Directors also believe that following the Transfer, the Company could gain wider recognition among larger institutional and retail investors. The Directors consider that the listing of the H Shares on the Main Board will be beneficial to the future growth, financial flexibility and business development of the Company. No change in nature of business of the Company is contemplated as at the date of this announcement by the Directors following the Transfer. The Transfer will not involve any issue of new H Shares by the Company.

DEALINGS IN THE H SHARES ON THE MAIN BOARD

The H Shares have been accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from 31 October 2000, the date on which the H Shares were listed on GEM. Subject to the continued compliance with the stock admission requirements of HKSCC, the H Shares will continue to be accepted as eligible securities by HKSCC for deposit, clearance and settlement in the CCASS once dealings in the H Shares on the Main Board commence, and that all activities under CCASS are subject to the General Rules of the CCASS and CCASS Operational Procedures in effect from time to time.

The last day of dealings in the H Shares on GEM will be 8 July 2010. Dealings in the H Shares on the Main Board (Stock code: 1666) will commence at 9:30 a.m. on 9 July 2010.

The Transfer will have no effect on the existing share certificates in respect of the H Shares which will continue to be good evidence of legal title and be valued for trading, settlement and registration purpose and will not involve any transfer or exchange of the existing share certificates. Currently, the H Shares have a board lot size of 1,000 H Shares each and are traded in Hong Kong Dollar. The share registrar of the Company in Hong Kong is Hong Kong Registrars Limited. No change will be made to the existing share certificates, board lot size, trading currency and the share registrars of the H Shares in connection with the Transfer.

H Shares will be traded under the new stock code 1666 on the Main Board in board lot size of 1,000 H Shares each following the Transfer.

COMPETING INTERESTS

Traditional Chinese medicines produce a broad range of curative effects as they can be used to treat the external symptoms of a disease and regulate other functions of the body that directly or indirectly give rise to such disease. To find the specific ways to treat a disease, it is necessary to consider a number of variables such as the state of illness, gender, age and constitution of a patient, the weather and the curative effects on the implicit problems of the patient. As such, a single type of traditional Chinese medicine usually has several curative effects, some of which may be similar to those of other products with different names or types.

Both of the Company and Tong Ren Tang Ltd. engage in the production of Chinese patent medicines. Their businesses are classified by the forms of medicine they produce. Tong Ren Tang Ltd. mainly produces Chinese patent medicines in traditional Chinese medicine forms such as honeyed pills, powder, ointment and medicinal wines. It also has some minor production lines for the production of granules and pills in western medicine forms which have already formed part of its products since the Company's listing on GEM in October 2000. These products do not compete with the Group in terms of their curative effects which accounted for about 12% of Tong Ren Tang Ltd.'s medicine sales in 2009. On the other hand, the Company focuses on manufacturing products in western medicine forms of granules, pills, tablets and soft capsules. Tong Ren Tang Ltd.'s main products include Kunbao Pills (坤寶丸), Tongren Wuji Baifeng Pills (同仁烏雞白鳳丸), Tongren Dahuoluo Pills (同仁大活絡丸), Guogong Wine (國公酒) and Angong Niuhuang Pills (安宮牛黃丸). Tong Ren Tang Group is an investment holding company and is not involved in the production of Chinese patent medicines. Neither Tong Ren Tang Ltd. nor Tong Ren Tang Group intends to inject its Chinese medicines business into the Company in the future.

Although the Company and Tong Ren Tang Ltd. engage in the production and sale of Chinese patent medicines, the principal products of each of these companies are different. The Company focuses on new forms of products which are more competitive against western pharmaceutical products, while Tong Ren Tang Ltd. continues to focus on the development of existing forms of traditional Chinese medicines. Below please find a table which sets out the principal products of Tong Ren Tang Ltd. and the Company.

Principal Products

Tong Ren Tang Ltd.	<ul style="list-style-type: none">• Kunbao Pills (坤寶丸);• Tongren Wuji Baifeng Pills (同仁烏雞白鳳丸);• Tongren Dahuoluo Pills (同仁大活絡丸);• Guogong Wine (國公酒); and• Angong Niuhuang Pills (安宮牛黃丸)
Company	<ul style="list-style-type: none">• Liuwei Dihuang Pills (六味地黃丸) ;• Niuhuang Jiedu Tablets (牛黃解毒片) ;• Ganmao Qingre Granule (感冒清熱顆粒) ;• Jin Kui Shenqi Pills (金匱腎氣丸); and• Shengmai Liquor (生脈飲)

To ensure that the business classification between the Company, Tong Ren Tang Group and Tong Ren Tang Ltd. are properly documented and established an undertaking where Tong Ren Tang Group and Tong Ren Tang Ltd. undertake, pursuant to an undertaking dated 19 October 2000 committed by Tong Ren Tang Group and Tong Ren Tang Ltd. in favor of the Company (“October Undertaking”), that other than Angong Niuhuang Pills (安宮牛黃丸), Tong Ren Tang Group, Tong Ren Tang Ltd. and their respective subsidiaries will not produce in future any products that bear the same names or bear the same names with different forms as those pharmaceutical products produced by the Company, and that may compete directly with those pharmaceutical products of the Company. Only one of the products – Angong Niuhuang Pills (安宮牛黃丸) – are manufactured by both the Company and Tong Ren Tang Ltd..

The Directors consider that other than Angong Niuhuang Pills (安宮牛黃丸) produced by the Company and Tong Ren Tang Ltd., there is no other directly competing businesses amongst the Company, Tong Ren Tang Ltd. and Tong Ren Tang Group. The Directors consider that as Angong Niuhuang Pills (安宮牛黃丸) only represents approximately 5.32%, 6.32% and 6.57% of the Company’s total sales of medicines in 2007, 2008 and 2009 respectively and it is not one of the major forms of medicine for development by the Company, the Company will continue to manufacture and sell Angong Niuhuang Pills (安宮牛黃丸). However, the Company has no intention to expand its production and sales of Angong Niuhuang Pills in the future. Save as mentioned herein, the Directors confirm that none of the products of the Company is in competition with Tong Ren Tang Ltd. or Tong Ren Tang Group in terms of their forms of medicines and their curative effects.

To procure that the Company focuses on the development of the four major forms of products (namely granules, pills, tablets and soft capsules), Tong Ren Tang Ltd. has granted the Company, pursuant to the October Undertaking, a right of first refusal to manufacture and sell any of the new products which is developed by Tong Ren Tang Ltd. or any of its subsidiaries and which is one of the four main forms of the Company. Upon exercise of the right of first refusal, Tong Ren Tang Ltd. and its subsidiaries are not allowed to manufacture any of such new products. In the event that the Company develops any new product based on the existing products of Tong Ren Tang Ltd. or its subsidiaries, and such new product is one of the major forms of the Company, the Company will be entitled to manufacture such new product and Tong Ren Tang Ltd. and its subsidiaries will not be allowed to manufacture such new product. The Directors believe that the above undertaking would clarify that Tong Ren Tang Ltd. would support the Company in its development of the four major forms of products in the future.

To procure that Company conducts an independent review of the research and development of new products and the development capability, the Company confirms that among the independent non-executive Directors, a reputable person in the traditional Chinese medicinal sector will determine whether to exercise the right of first refusal granted by Tong Ren Tang Ltd. to develop any proposed new products which is one of the major forms (namely granules, pills, tablets and soft capsules) of the Company. In the event that the Company refuses the right of first refusal offered by Tong Ren Tang Ltd., the terms of the option to be offered to an independent third party should not be more favourable than those originally offered to the Company, failing which the Company should be given an opportunity to re-consider the option under the new terms. The above undertaking would no longer be valid in the event that the direct or indirect aggregate shareholdings of Tong Ren Tang Ltd. in the Company fall below 30%.

Moreover, Tong Ren Tang Group and Tong Ren Tang Ltd. confirm that the Company and its independent non-executive Directors will implement the following:-

- (i) the independent non-executive Directors will review, at least on an annual basis, the compliance with the non-competition undertaking by Tong Ren Tang Group and Tong Ren Tang Ltd. the options, pre-emptive rights or first rights of refusals provided by Tong Ren Tang Ltd. and Tong Ren Tang Group on their existing or future competing businesses;
- (ii) Tong Ren Tang Ltd. and Tong Ren Tang Group have undertake to provide all information necessary for the annual review by the independent non-executive Directors and the enforcement of the non-competition undertaking;
- (iii) the Company will disclose decisions on matters reviewed by independent non-executive Directors in relation to the compliance and enforcement of the undertaking (e.g. the exercise of options or first rights of refusals) either through the annual report, or by way of announcements to the public; and
- (iv) an annual declaration by Tong Ren Tang Ltd. and Tong Ren Tang Group on compliance with the non-competition undertaking in the annual report of the Company.

DOCUMENTS AVAILABLE FOR INSPECTION

Copies of the following documents will be made available for inspection on the website of the Company at <http://www.tongrentangkj.com> and the Stock Exchange <http://www.hkexnews.hk>:

- (a) the Articles of Association of the Company;
- (b) first quarterly results announcement for the three months ended 31 March 2010 dated 26 April 2010;
- (c) the annual report for the year ended 31 December 2009 dated 29 March 2010;
- (d) the interim report for the six months ended 30 June 2009 dated 10 August 2009;
- (e) the circular of the Company dated 30 April 2009 with respect to the proposed amendment of Articles of Association and re-election and election of directors and supervisors and notice of AGM; and
- (f) a copy of each of the announcements and other corporate communications made by the Company as required under the GEM Listing Rules and the Listing Rules.

BIOGRAPHICAL DETAILS OF THE DIRECTORS AND SUPERVISORS

The Company discloses below the biographical information of each current Director or Supervisor of the Company:

EXECUTIVE DIRECTORS

Mr. Mei Qun (梅群), aged 54, chairman of the Company, is a deputy chief pharmacist. Mr. Mei obtained his master's degree in commerce and economy from the Chinese Academy of Social Science Graduate School in 1997. He was formerly the deputy chief of the education section of Beijing Tong Ren Tang Pharmacy Factory, assistant to the manager of Beijing Medicinal Materials Company, assistant to the general manager and deputy general manager of Tong Ren Tang Group, general manager of Tong Ren Tang Ltd., and vice chairman of the Company. He is currently deputy secretary to the Party Committee, the vice chairman and general manager of Tong Ren Tang Group, the chairman of Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd., the chairman of Beijing Tong Ren Tang Medicinal Materials Co., Ltd., the chairman of Beijing Tong Ren Tang Pharmaceutical Co., Ltd., the chairman of Beijing Tong Ren Tang Biological Product Development Co., Ltd., the chairman of Beijing Tong Ren Tang Minan Pharmaceutical Co., Ltd., the vice chairman of Tong Ren Tang Ltd., the vice chairman of Beijing Tong Ren Tang Chinese Medicine Company Limited and a director of Beijing Tong Ren Tang International Co., Ltd.. As the business scope of Tong Ren Tang Group is investment holding in equity interest, the day to day management workload of Mr. Mei is minimal. Moreover, although Mr. Mei is the vice chairman of Tong Ren Tang Ltd., he is not involved in the day to day management of Tong Ren Tang Ltd.. He is the vice president of Chinese Society of Traditional Chinese Medicine, a standing committee member of Beijing Pharmaceutical Association, an executive committee member of Beijing Trade and Industry Association, the vice president of Beijing Enterprise Confederation, the vice president of Chongwen General Chamber of Commerce, a member of China Council for the Promotion of International Trade and a standing committee member of China Association of Trade in Services. He was also a delegate to the Beijing 13th National People's Congress, a delegate to the Chongwen 13th and 14th National People's Congress. He is responsible for the

overall decision-making of the Company. He is the compliance officer of the Company and is responsible for overseeing all matters relating to the listing of the Company. He is one of the promoters of the Company. Mr. Mei was appointed as an executive Director on 9 March 2000 and was re-elected at the annual general meetings in 2003, 2006 and 2009.

Mr. Mei entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

As at the date of this announcement, Mr. Mei is interested in a total of 500,000 Domestic Shares, representing approximately 0.255% of the entire issued share capital of the Company; 37,297 shares, representing approximately 0.007% of the entire issued share capital of Tong Ren Tang Ltd. and 78,000 shares, representing approximately 0.250% of the entire issued share capital of Beijing Tong Ren Tang International Co., Ltd. that is a subsidiary of Tong Ren Tang Group.

Mr. Mei does not receive any director's fee but receive annual remuneration, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Mr. Yin Shun Hai (殷顺海), aged 57, is a senior economist. Mr. Yin obtained his master's degree in commerce and economy from the Chinese Academy of Social Science Graduate School in 1997. He was formerly the factory manager of Factory 2 of Tong Ren Tang Pharmacy Factory, the deputy general manager and general manager of Tong Ren Tang Group, and the chairman of the Company. He is currently the chairman and the secretary to the Party Committee of Tong Ren Tang Group, vice chairman of Tong Ren Tang Ltd., vice president of Patent Protection Association of China, an executive member of the 9th All-China Federation of Industry & Commerce and a delegate to the 11th Beijing's Chinese People's Political Consultative Conference. As the business scope of Tong Ren Tang Group is investment holding in equity interest, the day to day management workload of Mr. Yin is minimal. Moreover, as a vice chairman of Tong Ren Tang Ltd., Mr. Yin is not involved in the day to day management of Tong Ren Tang Ltd.. He is one of the promoters of the Company. Mr. Yin was appointed as an executive Director on 9 March 2000 and was re-elected at the annual general meetings in 2003, 2006 and 2009.

Mr. Yin entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

As at the date of this announcement, Mr. Yin is interested in a total of 500,000 Domestic Shares, representing approximately 0.255% of the entire issued share capital of the Company; 46,620 shares, representing approximately 0.009% of the entire issued share capital of Tong Ren Tang Ltd. and 39,000 shares, representing approximately 0.125% of the entire issued share capital of Beijing Tong Ren Tang International Co., Ltd. that is a subsidiary of Tong Ren Tang Group.

Mr. Yin does not receive any director's fee but receive annual remuneration, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Mr. Wang Yu Wei (王煜炜), aged 43, is a senior engineer. Mr. Wang obtained his master's degree in economic management from Party School of the Central Committee of Communist Party of China in 1999. He formerly served as the deputy officer of the new technology development centre and the deputy factory manager of Factory 2 of Beijing Tong Ren Tang Pharmacy Factory, the assistant to the general manager and the deputy general manager of the Company. He is currently the general manager of the Company, the director of Beijing Tong Ren Tang Chinese Medicine Company Limited and the chairman of Beijing Tong Ren Tang Nansanhuan Zhonglu Drugstore Co., Ltd.. He is also a delegate to the Fengtai District's 14th National People's Congress of Beijing. Mr. Wang was appointed as an executive Director on 25 June 2009.

Mr. Wang entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

Mr. Wang does not receive any director's fee but receive annual remuneration, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Ms. Fang Jia Zhi (房家志), aged 44, is a senior auditor. Ms. Fang obtained her bachelor's degree in accounting from Beijing Technology and Business University in 2001. She formerly served as the deputy head and head of audit department of Tong Ren Tang Group, the deputy chief accountant of the Company. She is currently the chief accountant of the Company, the director of Beijing Tong Ren Tang Yanbian Chinese Medicinal Raw Materials Co., Ltd., Beijing Tong Ren Tang Anhui Chinese Medicinal Raw Materials Co., Ltd., Beijing Tong Ren Tang Zhejiang Chinese Medicinal Raw Materials Co., Ltd., Beijing Tong Ren Tang Hebei Chinese Medicinal Raw Materials Technologies Co., Ltd., Beijing Tong Ren Tang Hubei Chinese Medicinal Raw Materials Co., Ltd., Beijing Tong Ren Tang Nanyang Shanzhuyu Co., Ltd., Beijing Tong Ren Tang Tongke Pharmaceutical Company Ltd. and Beijing Tong Ren Tang WM Dianorm Biotech Co., Ltd.. Ms. Fang was appointed as an executive Director on 25 June 2009.

Ms. Fang entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

Ms. Fang does not receive any director's fee but receive annual remuneration, which is determined with reference to her qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Mr. Xie Zhan Zhong (谢占忠), aged 58, is a senior economist with a bachelor's degree. Mr. Xie has previously served various positions in the Group, such as the section chief of the cadre administration department, the deputy chief economist as well as the manager of human resources department, the deputy chief economist, an assistant to the general manager, the deputy general manager of the Group. Mr. Xie currently serves as the secretary to the Party Committee, the deputy general manager and the chief auditor of Tong Ren Tang Ltd. since 2006 and 2009 respectively. Mr. Xie mainly focuses on the audit work of Tong Ren Tang Ltd. and except for the audit related work, he is not involved in the day-to-day management work of Tong Ren Tang Ltd.. As such, Mr. Xie can have enough time to be spent on the day-to-day

management work of the Company. Save as disclosed above, Mr. Xie does not have any other major appointments or qualifications or any position or directorship in any other listed companies during the last three years preceding the date of this announcement.

Mr. Xie was appointed as a Director of the Company on 26 April 2010. The said proposed appointment of Mr. Xie will take effect from the date of the approval of the Shareholders by way of an ordinary resolution at the forthcoming general meeting on 18 June 2010. Mr. Xie, if appointed, will enter into a service contract with the Company and his proposed length of service with the Company will commence from the date of his appointment and up to the date of the annual general meeting to be convened in 2012. Pursuant to the articles of association of the Company, upon expiration of his term of directorship, Mr. Xie shall be eligible for re-election at a general meeting of the Company. The remuneration payable to Mr. Xie shall be determined by the shareholders at a general meeting pursuant to the articles of association of the Company and with reference to the recommendation provided by the remuneration committee of the Board in accordance with its terms of reference, by taking into account, among other matters, his duties and responsibilities in the Company.

Save as disclosed above, Mr. Xie does not have any relationships with any Directors, senior management, substantial or controlling shareholder of the Company nor have any interests in the shares of the Company within the meaning of Part XV of the SFO as at the date of this announcement.

NON-EXECUTIVE DIRECTOR

Ms. Ding Yong Ling (丁永玲), aged 47, vice chairman of the Company, is a deputy chief pharmacist. Ms. Ding obtained her bachelor's degree in international economy management from Party School of the Central Committee of Communist Party of China (中共中央党校) in 1997. She served as the deputy head of the foreign trade department, the deputy manager and manager of the import and export branch, under Tong Ren Tang Group, the manager of the import and export branch of Tong Ren Tang Ltd., the deputy general manager of the Company and the manager of the import and export branch of the Company as well as an assistant to the general manager of Tong Ren Tang Group. She currently serves as the deputy general manager of Tong Ren Tang Group, the managing director of Beijing Tong Ren Tang International Co., Ltd. and Tong Ren Tang Chinese Medicine, and director of Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd.. Ms. Ding was appointed as an executive Director on 16 May 2005 and was re-elected at the annual general meetings in 2006 and 2009. She was also appointed as a non-executive Director of the Company on 26 April 2010. Ms. Ding is not involved in the day to day management of the Company.

Ms. Ding entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

As at the date of this announcement, Ms. Ding is interested in a total of 39,000 shares, representing approximately 0.125% of the entire issued share capital of Beijing Tong Ren Tang International Co. Ltd. that is a subsidiary of Tong Ren Tang Group.

Ms. Ding does not receive any director's fee but receive annual remuneration, which is determined with reference to her qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Miss. Tam Wai Chu, Maria (譚惠珠), aged 65, GBS, JP, LL.D (Honoris Causa), LL.B (Honours), barrister. She is currently an independent non-executive director of seven listed companies namely Guangnan (Holdings) Limited, Minmetals Land Limited, Nine Dragons Paper (Holdings) Limited, Sa Sa International Holdings Limited, Sinopec Kantons Holdings Limited, Titan Petrochemicals Group Limited and Wing On Company International Limited, all are listed on The Stock Exchange of Hong Kong Limited. She was a member of the Preparatory Committee for the Hong Kong Special Administrative Region (PRC) and Hong Kong Affairs Advisor (PRC). She is currently a member of the Task Group on Constitutional Development of the Commission on Strategic Development. She is a Deputy to the National People's Congress of The People's Republic of China and a member of the Hong Kong Basic Law Committee. Miss. Tam was appointed as an independent non-executive Director on 11 October 2000 and was re-elected at the annual general meetings in 2003, 2006 and 2009.

Miss. Tam is entitled HK\$ 180,000 per annum, as director's fee, which is determined with reference to her qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Mr. Ting Leung Huel, Stephen (丁良輝), MH, FCCA, FCPA (Practising), ACA, FTIHK, FHKID, aged 57, is the chairman of the audit committee and a member of the remuneration committee of the Company. He is a non-executive director of Chow Sang Sang Holdings International Limited and an independent non-executive director of six listed companies namely Tongda Group Group Limited, Minmetals Resources Limited, JLF Investment Company Limited, Computer And Technologies Holdings Limited, Texhong Textile Group Limited and Dongyue Group Limited respectively. In the last three years, he held directorship at eForce Holdings Limited but was subsequently resigned. Save as disclosed above, Mr. Ting has not held any directorship in other listed public companies in the past three years. Mr. Ting is a member of the 9th and 10th Chinese People's Political & Consultative Conference, Fujian. Mr. Ting is an accountant in public practice and the managing partner of Messrs. Ting Ho Kwan & Chan, Certified Public Accountants (Practising). Mr. Ting was appointed as an independent non-executive Director on 11 October 2000 and was re-elected at the annual general meetings in 2003, 2006 and 2009.

Mr. Ding is entitled HK\$ 180,000 per annum, as director's fee, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Mr. Jin Shi Yuan (金世元), aged 84, a chief pharmacist, is the Chinese medicine investigation expert in state secret technology for the State Science and Technology Commission, evaluation expert in Chinese medicine project for the National Natural Science Foundation of China, appraisal expert in science and technology achievements for the State Administration of Traditional Chinese Medicine, appraisal expert in basic medicines for the State Food and Drug Administration, appraisal expert in Chinese medicine prices for the State Development and Reform Commission, and successor to Chinese medicine preparations in State nonmaterial cultural heritages. Mr. Jin is also a lifelong councilor of the China Association of Traditional Chinese Medicine, Chairman of the Chinese Patent Medicine Affiliate, member of the Committee on Clinical Medicine Evaluation Experts, consultant to the Council of Beijing Institute of Chinese Medicine and guest professor of the School of Chinese Medicine, Capital University of Medical Sciences, and Capital Renowned Expert of

Chinese Medicine. Mr. Jin was appointed as an independent non-executive Director on 16 October 2000 and was re-elected at the annual general meetings in 2003, 2006 and 2009.

Mr. Jin is entitled RMB 48,000 per annum, as director's fee, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

SUPERVISORS

Mr. Zhang Xi Jie (張錫傑), aged 56, Chief Supervisor of the Company, is a senior accountant and Chinese certified public accountant. Mr. Zhang obtained his master's degree in commerce and economy from Chinese Academy of Social Science Graduate School in 1997. He served as deputy head of finance department of Beijing Medicine Company, head of finance, accounting and pricing department, deputy manager of capital operation department of Beijing Medicine Group Limited, executive deputy head, head and deputy chief accountant of the development office of Tong Ren Tang Group. He is currently a director and the chief accountant of Tong Ren Tang Group and the chairman of the supervisory committee of Tong Ren Tang Ltd., the chairman of Beijing Tong Ren Tang Commercial Investment Management Co., Ltd., director of Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd. and Beijing Tong Ren Tang Medicinal Materials Co., Ltd. and Beijing Tong Ren Tang Pharmaceutical Co., Ltd. and Beijing Tong Ren Tang Biological Product Development Co., Ltd.. Mr. Zhang was appointed as a Supervisor at the annual general meeting in 2006 and was re-elected at the annual general meeting in 2009.

Mr. Zhang entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

Mr. Zhang does not receive any supervisor's fee but receive annual remuneration, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Mr. Wu Yi Gang (吳以綱), aged 52, obtained his bachelor of law degree from Beijing University in 1983. He was admitted as a solicitor in 1984 and started practice in the same year. Mr. Wu founded Wu Luan Zhao Yan Law Firm in Beijing in 1994 and has been the managing partner of the firm since then. He served as one of the arbitrators of the first session of the Beijing Arbitration Commission in 1995. He currently serves as the deputy director of Foreign Affairs Committee of Beijing Lawyers Association, and member of the First Council of Beijing Club of Non-Party Senior Intellectuals. Mr. Wu was appointed as a Supervisor of the Company on 22 October 2003 and was re-elected at the annual general meetings in 2006 and 2009.

Mr. Wu entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

Mr. Wu is entitled RMB 48,000 per annum, as supervisor's fee, which is determined with reference to his qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Ms. Wang Yan Rong (王彦榮), aged 49, is an economist. Ms. Wang obtained his bachelor's degree in accounting from the Open University of China in 2005. She served as the section officer of human resources department and Administrative Office, deputy department head and department head of Manager Office of Tong Ren Tang Group. She is currently the deputy secretary to the Party Committee, the secretary to the Disciplinary Committee and the chairman of the labour union of the Company. Ms. Wang was appointed as a Supervisor on 25 June 2009.

Ms. Wang entered into a service contract with the Company for a term of three years commencing from 25 June 2009 to the conclusion of the annual general meeting in 2012, renewable for successive terms of three years from 2012 subject to retirement and re-election by Shareholders of the Company pursuant to the Articles of Association of the Company.

Ms. Wang does not receive any supervisor's fee but receive annual remuneration, which is determined with reference to her qualification and experience, duties and responsibilities to be undertaken and the prevailing market level of remuneration of similar position.

Save as disclosed above, none of the Directors (i) has held any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) has held any position with the Company or its subsidiaries; (iii) as at the date of this announcement, has any interest in the Shares which required to be disclosed under Part XV of the Securities and Future Ordinance; and (iv) has any relationship with any other directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed above, there is no information relating to the Directors that is required to be disclosed pursuant to Rules 13.51(2)(h)-(v) of the Main Board Listing Rules and the Board is not aware of any other matter that needs to be brought to the attention of the Shareholders in relation to their directorships.

DEFINITIONS

"Articles of Association"	the current articles of association of the Company
"Board"	the board of Directors
"CCASS"	the Central Clearing and Settlement System established and operated by HKSCC
"Company"	Tong Ren Tang Technologies Co., Ltd., a company incorporated in the PRC with limited liability and the issued H Shares of which are listed on GEM
"Director(s)"	director(s) of the Company from time to time
"Domestic Shares"	the domestic share(s) with a nominal value of RMB1.00 each in the share capital of the Company which are subscribed for and paid up in RMB

"GEM"	the Growth Enterprise Market of the Stock Exchange
"GEM Listing Rules"	The Rules Governing the Listing of Securities on GEM
"Group"	the Company and its subsidiaries
"H Share(s)"	the overseas listed foreign invested share(s) with a nominal value of RMB1.00 each in the share capital of the Company which are listed on GEM and are subscribed for and traded in Hong Kong dollars
"HKSCC"	Hong Kong Securities Clearing Company Limited
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"HK\$"	Hong Kong Dollar, the lawful currency of Hong Kong
"Listing Committee"	the listing committee of the board of directors of the Stock Exchange
"Listing Rules"	The Rules Governing the Listing of Securities on the Stock Exchange
"Main Board"	the stock market operated by the Stock Exchange prior to the establishment of GEM (excluding the options market) which stock market continues to be operated by the Stock Exchange in parallel with GEM. For the avoidance of doubt, the Main Board excludes GEM
"PRC"	the People's Republic of China, which for the purposes of this announcement, excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"RMB"	Renminbi, the lawful currency of the PRC
"Shareholder(s)"	holder(s) of the H Shares and Domestic Shares
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Supervisor(s)"	Supervisor(s) of the Company
"Transfer"	the transfer of listing of the H Shares from GEM to the Main Board pursuant to the Listing Rules
"Tong Ren Tang Group"	China Beijing Tong Ren Tang Group Co., Ltd. (中國北京同仁堂(集團)有限責任公司), a state-owned enterprise established in the PRC under the laws of the PRC and the ultimate holding company of the Company and the holding company of Tong Ren Tang Ltd.

"Tong Ren Tang Ltd." Beijing Tongrentang Company Limited (北京同仁堂股份有限公司), a joint stock limited company established in the PRC, the shares of which have been listed on the Shanghai Stock Exchange A Shares Market since 1997, and is the holding company of the Company

"%" percent.

By order of the Board
Tong Ren Tang Technologies Co., Ltd.

Mei Qun
Chairman

Beijing, the PRC, 18 June 2010

As at the date of this announcement, the Board comprises (i) Mr. Mei Qun, Mr. Yin Shun Hai, Mr. Wang Yu Wei, Ms. Fang Jia Zhi and Mr. Xie Zhan Zhong as executive Directors; (ii) Ms. Ding Yong Ling as non-executive Director; and (iii) Ms. Tam Wai Chu, Maria, Mr. Ting Leung Huel, Stephen and Mr. Jin Shi Yuan as independent non-executive Directors.

This announcement for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the "Latest Company Announcements" page for at least 7 days from the day of its posting and be posted on our website at <http://www.tongrentangkj.com>.